Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical Companies has filed a supplemental marketing application with the FDA seeking approval to use Darzalex (daratumumab), combined with Amgen’s (NASDAQ:AMGN) Kyprolis (carfilzomib) and dexamethasone, to treat patients with relapsed/refractory multiple myeloma (MM).
The agency first approved the CD38-directed
cytolytic antibody in November 2015 for previously treated MM. It
subsequently approved five additional uses (mostly combinations) in MM.
https://seekingalpha.com/news/3540289-j-and-j-files-u-s-application-for-expanded-use-of-darzalex
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.